Literature DB >> 3940683

Frequency and clustering of nonlipid coronary risk factors in dyslipoproteinemia. The Lipid Research Clinics Program Prevalence Study.

M H Criqui, L D Cowan, G Heiss, W L Haskell, P M Laskarzewski, L E Chambless.   

Abstract

In a defined population of 4349 men and 3398 women, we evaluated the frequency and clustering of five nonlipid coronary heart disease risk factors--obesity, hypertension, sedentary lifestyle, cigarette smoking, and alcohol consumption--in nine categorical lipoprotein phenotypes--normal, types I or V, IIA, IIB, III, IV, hypoHDL (high-density lipoprotein), hypoLDL (low-density lipoprotein), and hyperHDL. This analysis indicated that compared with the normal phenotype, nonlipid coronary risk factors tend to be more frequent and thus cluster in individuals with "high risk" phenotypes, and occur somewhat less frequently in those with "low risk" phenotypes. Thus, identification of a high-risk phenotype suggests the presence of nonlipid risk factors as well, and the clinician should be alert to this possibility. A multivariable analysis of the independent associations of each of the risk factors with the lipid and lipoprotein components that define the phenotypes suggested that several behavioral risk factors may directly affect lipid and lipoprotein levels. This observation raises the possibility that certain intervention strategies, such as weight loss, smoking cessation, and regular exercise, may favorably influence dyslipoproteinemia.

Entities:  

Mesh:

Year:  1986        PMID: 3940683

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

1.  Maternal influences on body satisfaction in Black and White girls aged 9 and 10: The NHLBI Growth and Health Study (NGHS).

Authors:  K M Brown; G B Schreiber; R P McMahon; P Crawford; K L Ghee
Journal:  Ann Behav Med       Date:  1995-09

2.  A pilot study of community cholesterol screening.

Authors:  C Scheidt-Nave; E Barrett-Connor; M H Criqui; K T Khaw
Journal:  Soz Praventivmed       Date:  1988

3.  Metabolic Clusters and Outcomes in Older Adults: The Cardiovascular Health Study.

Authors:  Kenneth J Mukamal; David S Siscovick; Ian H de Boer; Joachim H Ix; Jorge R Kizer; Luc Djoussé; Annette L Fitzpatrick; Russell P Tracy; Edward J Boyko; Steven E Kahn; Alice M Arnold
Journal:  J Am Geriatr Soc       Date:  2018-02       Impact factor: 5.562

4.  The role of insulin in clustering of serum lipids and blood pressure in children and adolescents. The Cardiovascular Risk in Young Finns Study.

Authors:  O T Raitakari; K V Porkka; T Rönnemaa; M Knip; M Uhari; H K Akerblom; J S Viikari
Journal:  Diabetologia       Date:  1995-09       Impact factor: 10.122

5.  Association between sympathetic activity and the atherogenic serum cholesterol fraction.

Authors:  P Weidmann; D C Schohn; W Riesen; H A Jahn; P Ferrari; S G Shaw; C Beretta-Piccoli
Journal:  Klin Wochenschr       Date:  1990-03-05

6.  A cluster of metabolic defects caused by mutation in a mitochondrial tRNA.

Authors:  Frederick H Wilson; Ali Hariri; Anita Farhi; Hongyu Zhao; Kitt Falk Petersen; Hakan R Toka; Carol Nelson-Williams; Khalid M Raja; Michael Kashgarian; Gerald I Shulman; Steven J Scheinman; Richard P Lifton
Journal:  Science       Date:  2004-10-21       Impact factor: 47.728

7.  Relationship of alcohol consumption and type of alcoholic beverage consumed with plasma lipid levels: differences between Whites and African Americans of the ARIC study.

Authors:  Kelly A Volcik; Christie M Ballantyne; Flavio D Fuchs; A Richey Sharrett; Eric Boerwinkle
Journal:  Ann Epidemiol       Date:  2007-09-14       Impact factor: 3.797

8.  Obesity and cardiovascular disease risk factors in black and white girls: the NHLBI Growth and Health Study.

Authors: 
Journal:  Am J Public Health       Date:  1992-12       Impact factor: 9.308

9.  Epidemiology of cardiovascular disease risk factors in Catalonia (Spain).

Authors:  P Plans; H Pardell; L Salleras
Journal:  Eur J Epidemiol       Date:  1993-07       Impact factor: 8.082

10.  A randomized, double blind, placebo-controlled, multicenter phase II trial of Allisartan Isoproxil in essential hypertensive population at low-medium risk.

Authors:  Ying Li; Xiao-hui Li; Zhi-jun Huang; Guo-ping Yang; Guo-gang Zhang; Shui-ping Zhao; Ying Guo; Shi-juan Lu; Jian-lin Ma; Fan-bo Meng; Ping Chen; Hong Yuan
Journal:  PLoS One       Date:  2015-02-18       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.